NCT07664956Not yet recruitingPhase 4
Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy
Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 24 Jun 2026
Brief summary (registry, in English)
Typical postoperative pain control after minimally invasive hysterectomy includes ibuprofen, acetaminophen, and a short course of narcotics. The purpose of this study is to see if adding cyclobenzaprine to this regime improves pain control and lessens narcotic use.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- First submitted
- 3 Mar 2026
- Start date
- 1 Jul 2026
- Primary completion date
- 1 Sept 2026
- Lead sponsor
- Christiana Care Health Services
- Diseases
- Endometriosis
- NCT number
- NCT07664956
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 36
- From 1 Jul 2026 to the primary completion date, 1 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Laparoscopic resection of endometriosis
- Procedures with planned or unplanned bladder or bowel surgery
- Currently using opioids consistently
- Patient's receiving gabapentin at baseline or postoperatively, due to potential sedating effects, or other sedating drugs such as scheduled benzodiazepines and barbiturates
Other illness
- Allergies or contraindications to standard post operative pain control medications (acetaminophen, NSAIDs, narcotics), such as kidney or liver damage/failure, bariatric surgery, history of gastric ulcer, etc.
- Currently undergoing medication assisted treatment for opioid use disorder
- Allergies or contraindications to cyclobenzaprine:
- Absolute: use of MAO inhibitors within 14 days, recent heart attack, congestive heart failure, heart block or other conduction abnormalities, cardiac arrhythmias, hyperthyroidism, history of serotonin syndrome
- Allergies or contraindications to inactive ingredients in Flexeril, such as lactose
Age
- Age \<18yo
Other
- Male
- Pregnant, breastfeeding
- Non-English speaking
- Primary procedures other than laparoscopic hysterectomy
- Laparoscopic myomectomy
- Laparoscopic unilateral or bilateral salpingectomy ± unilateral or bilateral oophorectomy ± unilateral or bilateral cystectomy without hysterectomy
- Hysteroscopic procedures
- Bartholin gland marsupialization
- Operations that are scheduled as or converted to the open approach
- Chronic pain issues, whether self-diagnosed or by a physician, currently undergoing management
Who the study is looking for
- Age \>18yo
- Female
- English speaking
- Undergoing (robotic assisted or classic) total laparoscopic hysterectomy ± unilateral or bilateral salpingectomy ± unilateral or bilateral oophorectomy
- If other procedures such as lysis of adhesions, excision of endometriosis, or ureterolysis are indicated based on intraoperative evaluation, those patients may still be included
- Surgery took place at ChristianaCare Hospitals
- No allergies or contraindications to standard of care post operative pain medications (acetaminophen, NSAIDs, narcotics) or cyclobenzaprine
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| ChristianaCare Health System Coordinator of this site? Confirm its status | Newark | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.